

LISTING OF CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-22. (Cancelled).

23. (Previously Presented): A method of treating a ~~Flaviviridae~~ Dengue virus infection of a ~~mammal~~ human, wherein the infection is mediated at least in part by the binding of a ~~Flaviviridae~~ Dengue virus effector molecule on the ~~Flaviviridae~~ Dengue virus to a ~~DC-Specific ICAM-Grabbing Nonintegrin (DC-SIGN) receptor~~ one or more DC-SIGN receptor selected from DC-Specific ICAM-Grabbing Nonintegrin (DC-SIGN) and DC-Specific ICAM-Grabbing Nonintegrin Related (DC-SIGNR) of the ~~mammal~~ human to be treated, the method comprising:

administering to the ~~mammal~~ human a molecule that specifically binds to the DC-SIGN receptor;

wherein the molecule that specifically binds to the DC-SIGN receptor is administered in an amount sufficient to inhibit the binding of the ~~Flaviviridae~~ Dengue virus effector molecule to the DC-SIGN receptor to thereby treat the ~~Flaviviridae~~ Dengue virus infection.

24 and 25. (Cancelled).

26. (Original): The method of claim [[25]] 23, wherein the Dengue virus effector molecule is a molecular constituent of the Dengue virus envelope.

27. (Original): The method of claim 26, wherein the molecular constituent of the Dengue virus envelope is a Dengue virus envelope glycoprotein.

28. (Original): The method of claim 27, wherein the Dengue virus envelope glycoprotein is Dengue virus E glycoprotein.

29. (Currently Amended): The method of claim [[25]] 23, wherein the molecule that specifically binds to the DC-SIGN receptor comprises a binding moiety of the Dengue virus effector molecule, wherein the binding moiety specifically binds to the DC-SIGN receptor.

30. (Previously Presented): The method of claim 28, wherein the molecule that specifically binds to the DC-SIGN receptor comprises a binding moiety of the Dengue virus E glycoprotein, wherein the binding moiety specifically binds to the DC-SIGN receptor.

31. (Withdrawn): The method of claim 30, wherein the molecule that specifically binds to the DC-SIGN receptor is a recombinantly produced protein.

32. (Currently Amended): The method of claim ~~[[25]]~~ 23, wherein the molecule that specifically binds to the DC-SIGN receptor is an antibody.

33. (Original): The method of 32, wherein the antibody is a monoclonal antibody.

34. (Currently Amended): The method of claim 33, wherein the ~~mammal is a human and the~~ monoclonal antibody is humanized.

35-71. (Cancelled).

72. (Withdrawn): The method of claim 23, wherein the molecule that specifically binds to the DC-SIGN receptor is a mannosylated molecule.

73. (Withdrawn): The method of claim 72, wherein the mannosylated molecule is mannan.

74 and 75. (Cancelled).

76. (Withdrawn): The method of claim 28, wherein the molecule that specifically binds to the DC-SIGN receptor is a mannosylated molecule.

77. (Withdrawn): The method of claim 76, wherein the mannosylated molecule is mannan.

78. (Currently Amended): A method of inhibiting entry of a ~~Flaviviridae~~ Dengue virus into a cell of a ~~mammal~~ human that expresses a ~~DC-SIGN receptor~~ one or more DC-SIGN receptor selected from DC-SIGN and DC-SIGNR, wherein entry of the ~~Flaviviridae~~ Dengue virus into the cell of the ~~mammal~~ human is mediated at least in part by binding of a ~~Flaviviridae~~ Dengue virus effector molecule on the ~~Flaviviridae~~ Dengue virus to the DC-SIGN receptor on the cell of the ~~mammal~~ human, the method comprising:

administering to the ~~mammal~~ human a molecule that specifically binds to the DC-SIGN receptor;

wherein the molecule that specifically binds to the DC-SIGN receptor is administered in an amount sufficient to inhibit the binding of the ~~Flaviviridae~~ Dengue virus effector molecule to the DC-SIGN receptor to thereby inhibit entry of the ~~Flaviviridae~~ Dengue virus into the cell.

79-80. (Cancelled).

81. (Currently Amended): The method of claim ~~[[80]]~~ 78, wherein the Dengue virus effector molecule is a molecular constituent of the Dengue virus envelope.

82. (Previously Presented): The method of claim 81, wherein the molecular constituent of the Dengue virus envelope is a Dengue virus envelope glycoprotein.

83. (Previously Presented): The method of claim 82, wherein the Dengue virus envelope glycoprotein is Dengue virus E glycoprotein.

84. (Currently Amended): The method of claim ~~[[80]]~~ 78, wherein the molecule that specifically binds to the DC-SIGN receptor comprises a binding moiety of the Dengue virus effector molecule, wherein the binding moiety specifically binds to the DC-SIGN receptor.

85. (Previously Presented): The method of claim 83, wherein the molecule that specifically binds to the DC-SIGN receptor comprises a binding moiety of the Dengue virus E glycoprotein, wherein the binding moiety specifically binds to the DC-SIGN receptor.

86. (Withdrawn): The method of claim 85, wherein the molecule that specifically binds to the DC-SIGN receptor is a recombinantly produced protein.

87. (Currently Amended): The method of claim ~~[[80]]~~ 78, wherein the molecule that specifically binds to the DC-SIGN receptor is an antibody.

88. (Previously Presented): The method of 87, wherein the antibody is a monoclonal antibody.

89. (Currently Amended): The method of claim 88, wherein the ~~mammal is a human and the~~ monoclonal antibody is humanized.

90. (Withdrawn): The method of claim 78, wherein the molecule that specifically binds to the DC-SIGN receptor is a mannosylated molecule.

91. (Withdrawn): The method of claim 90, wherein the mannosylated molecule is mannan.

92 and 93 (cancelled).

94. (Withdrawn): The method of claim 83, wherein the molecule that specifically binds to the DC-SIGN receptor is a mannosylated molecule.

95. (Withdrawn): The method of claim 94, wherein the mannosylated molecule is mannan.

96-101. (Cancelled).

102. (Withdrawn; Currently Amended): The method of claim ~~[[80]]~~ 78, wherein the molecule that specifically binds to the DC-SIGN receptor is a recombinantly produced protein.

103. (Withdrawn; Currently Amended): The method of claim ~~[[96]]~~ 29, wherein the molecule that specifically binds to the DC-SIGN receptor comprises a binding moiety of the Dengue virus E glycoprotein, wherein the binding moiety specifically binds to the DC SIGN receptor.

104. (New): The method of claim 23, wherein the molecule that specifically binds to the DC-SIGN receptor is a recombinantly produced protein.

105. (New): The method of claim 84, wherein the molecule that specifically binds to the DC-SIGN receptor comprises a binding moiety of the Dengue virus E glycoprotein, wherein the binding moiety specifically binds to the DC SIGN receptor.